Myriad RBM, DaVita Labs to Collaborate on Protein Markers for Dialysis Management | GenomeWeb

Myriad RBM and DaVita Labs said this week that they have entered a collaboration agreement to identify protein biomarkers for the management of dialysis patients.

The companies plan to use Myriad RBM's immunoassay-based DiscoveryMAP platform for the project, which will initially focus on identifying markers for predicting vascular access failure.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.